Non-Analgesic Effects of Opioids: Opioid-induced Respiratory Depression

Abstract

Opioids induce respiratory depression via activation of μ-opioid receptors at specific sites in the central nervous system including the pre-Bötzinger complex, a respiratory rhythm generating area in the pons. Full opioid agonists like morphine and fentanyl affect breathing with onset and offset profiles that are primarily determined by opioid transfer to the receptor site, while the effects of partial opioid agonists such as buprenorphine are governed by transfer to the receptor site together with receptor kinetics, in particular dissociation kinetics. Opioid-induced respiratory depression is potentially fatal but may be reversed by the opioid receptor antagonist naloxone, an agent with a short elimination half-life (30 min). The rate-limiting factor in naloxone-reversal of opioid effect is the receptor kinetics of the opioid agonists that requires reversal. Agents with slow dissociation kinetics (buprenorphine) require a continuous naloxone infusion while agents with rapid kinetics (fentanyl) will show complete reversal upon a single naloxone dose. Since naloxone is non-selective and will reverse analgesia as well, efforts are focused on the development of compounds that reverse opioid-induced respiratory depression without affecting analgesic efficacy. Such agents include ampakines and serotonin agonists which are aimed at selectively enhancing central respiratory drive. A novel approach is aimed at the reduction of respiratory depression from opioid-activation of (micro-)glia cells in the pons and brainstem using micro-glia cell stabilizers. Since this approach simultaneously enhances opioid analgesic efficacy it seems an attractive alternative to the classical reversal strategies with naloxone.

Efficacious Vaccine against Heroin Contaminated with Fentanyl

“…17 Heroin and fentanyl work together to potentiate the effects of respiratory depression, namely potentially fatal brain hypoxia. 12 Our heroin–fentanyl admixture vaccine produces antibodies that effectively sequester each drug creating an antibody-drug complex that is too large to penetrate the blood- brain barrier.…”

Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms

“…Interestingly, the antinociceptive activity of buprenorphine was also demonstrated using visceromotor response to colorectal distension assay (Larauche et al, 2010). However, earlier studies, showing that buprenorphine may produce side effects typical for classical opioids, such as respiratory depression, dizziness or nausea (Boom et al, 2012), indicate the need to design the derivatives with similar pharmacological profile, but deprived of side effects typical for the parent compound.…”

Nalmefene for the treatment of alcohol dependence: a current update

“…Mu receptors play an essential role in mediating the analgaesic and rewarding effects of opioids and, very likely, also in physical dependence (Narita et al, 2001). The μ1 receptor subtype is linked to analgaesia and euphoria, the μ2 subtype to respiratory depression (Boom et al, 2012).…”